I-Mab

News

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.